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Latin-American people with dementia will increase to an astounding 368% in 2050,
higher than USA and Europe. In addition, to sporadic dementia type like Alzheimer,
and vascular dementia (VaD) progression after Cerebrovascular disease is also found.
These incidences are increased in Colombia by specific populations affected with pure
Neurodegenerative and VaDs like Autosomical Dominant familial Alzheimer’s disease
(AD) and Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL). In spite of the enormous human effort with and
economical effort and investment costs, neither sporadic nor genetic kinds of dementia
progression have been prevented or blocked yet. Currently, there exist several animal
models that partially solve the understanding of the neurodegenerative etiopathogenesis
and its treatment. However, when the potential therapies are translated to humans,
those do not work or present a limited action. Main difficulties are the diverse comorbility
associated to the cause and/or several affected brain regions, reducing the efficacy
of some therapies which are limited to a tissue-specific action or modulating a kind
of neurotransmission. Global investigation suggests that a general prevention could
be achieved with the improvement in the quality of lifestyle, including healthy diet,
physical and mental activity, and avoiding mechanical or chemical pro-inflammatory
events in an early stage in the most of non-communicable diseases. In this review
article, we present some molecular targets and preclinical studies in animal models
to propose strategies that could be useful in a future translation to prevent or block
neurodegeneration: one is gene therapy; silencing pathogenic genes in critical brain
areas where excitotoxicity arise and spread. Another is to take advantage of the natural
source and its wide biodiversity of natural products that are capable of identifying, by the
blocking and prevention of neurodegeneration. On the other side, the casuistic of pure
dementias in the Latin-American region gives an exceptional opportunity to understand
the pathogenesis in these human populations. Further, this is in support of the basic and
clinical researchers working on an interaction for a better understanding and medical
care of mixed dementias, which have more complex factors than pure ones. However,
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to promote the translation of any therapeutical alternative is necessary to clarify the
normative and the protocols for developing clinical trials with original candidates or work
upon strategies proposed from South-American countries.
Keywords: neurodegeneration, preclinical studies, pharmacological therapy, gene therapy, translational medicine
DEMENTIA EPIDEMIOLOGY: CHRONIC
AND ACUTE BRAIN INJURY
Mental and neurological disorders are prevalent worldwide.
Traditional epidemiological studies represent and indicate only
mortality levels, and seriously underestimate the social impact
of neurodegeneration; because it does not consider disability
levels. The latest report on the global burden of disease shows
that neurodegenerative disorders generate 1% of mortality; out
of the 11.2% of disability reported worldwide. Life expectancy
increase in industrialized and developing countries leads to
neurological disorders and are becoming a major public
health problem that could reach pandemic proportions in the
coming years. It is anticipated that by 2020 the levels of
disability due to neurological diseases will be above 14.7%
(WHO, 2016).
Dementia (Alzheimer’s disease (AD) type, vascular dementia
(VaD), and other dementias) is a disease that affects more
than 26 million people worldwide. Latin-American people
with dementia will increase in a 368% in 2050, higher
than USA and Europe (Informe ADI/Bupa, 2013; WHO,
2016). As a result of these statistical projections, clear and
detailed programs are needed for capacity building in Latin-
America to handle the volumes due to increased casuistic
(Gonzalez et al., 2014). The prevalence of Dementia is South
America exists in multiple variations due to Population, Age
Structure, Genetics, life style of people who are older than
65 years. In South America there exists a big variation in
the dementia prevalence, according to population indicators
like population age structure, Genetics and Lifestyle of people
older than 65 years, Whereas in Argentina (11.5%) and
Venezuela (10.3%) present a higher prevalence of dementia,
Cuba (8.2%), Brazil (5.3%), Perú (6.7%), Chile (4.3%) present
an intermediate prevalence, although some lower prevalence
exists in Colombia (1.8%), Uruguay (0.5%) and some cities
in Brazil (1%–2%) and in rural Perú (<1%; Kalaria et al.,
2008). In Colombia, people with dementia and other cognitive
disorders are increasing due to the closed relationship with
public health problems, such as metabolic disorders like diabetes,
hypertension, cerebrovascular disease and accidents. In the
Antioquia department in Colombia, the situation is more
critical, due to the high incidence of familial AD. On an
average more than 1000 individuals will develop the disease
before reaching old age, apart from other dementias like
Cerebral Autosomal-Dominant Arteriopathy with Subcortical
Infarcts and Leukoencephalopathy (CADASIL) with more
than 80 affected individuals per 1000. Also, an analog
situation occurs in Venezuela, with an estimated Huntington’s
disease prevalence of 720 per 100,000 habitants in Maracaibo
(Al-Jader et al., 2001).
AD is the most common cause of dementia in people
over 65 years of age, including more than 20 million
people are affected by sporadic AD worldwide. AD is
characterized by aggregated protein that forms amyloid plaques
and neurofibrillary tangles (NTFs), causing brain atrophy and
cognitive impairment progression leading to dementia. Protein’s
aggregates are a common feature of several neurodegenerative
diseases, however, some cellular accumulated proteins in the
senescent brains, do not cause cognitive disorders, suggesting
that, this might be the result of normal aging processes
(Przedborski et al., 2003). AD has an important vascular
component (Muresanu et al., 2014), and recently it has been
considered that early detection of proto-fibrillar amyloid in
young Familiar AD (FAD) patients by PET (Reiman et al., 2012),
could be an important biomarker for the prevention of vascular
deterioration, as the common cause of VaD. Nevertheless,
aggregation of the tau protein is an exception. Studies that
evaluate the brains of AD patients have found that the number of
NTFs correlates with dementia more accurately than the amyloid
plaques (Arriagada et al., 1992) in the later stage. This evidence
generates great interest for therapeutic intervention in AD and
other tauopathies (Ballatore et al., 2007), by chronic or acute
injuries.
VaD is the second most common type of dementia, small-
artery associated to hypertensive disease is a common cause
around the world (73%), but presenting a low prevalence
from 0.6% to 2.1% in people older to 65 years in developing
countries, maybe due to poor early diagnosis and a subdiagnosis
as mix dementia, which has a prevalence of 10% in Latin-
American (Kalaria et al., 2008). Mix dementia combines more
than one type of dementia presenting deposits associated to
AD and vascular affection, which may coexist with Lewy
bodies, typical of Parkinson’s dementia (Alzheimer’s association,
2016). Therefore, it is difficult to determine its prevalence,
based upon post-morten determination. However it is closely
correlated with the increased age and is also higher in the
senior patients in age above >85 year old. In addition these
symptoms depend upon the affected brain regions, but are also
commonly diagnosed as Alzheimer’s patients (94%), coexisting
with vascular disease and Lewy bodies and other such nonspecific
treatments have also been included (Alzheimer’s association,
2016).
On the other hand, developing countries have a higher level
of exposure to cerebrovascular risk factors, such as hypertension,
smoking, obesity and diabetes, than in developed countries (Rizzi
et al., 2014); which increase the probability for suffering an
ischemic stroke, which is a major risk factor for developing
VaD and AD (Vijayan and Reddy, 2016). Cerebral ischemia
is a type of stroke characterized by transient or permanent
decreas in blood flow due to thrombotic occlusion or embolic
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in one or more cerebral arteries. This results in the deprivation
of trophic factors, metabolic substrates and the activation of
cell death pathways (Roberts et al., 2013). Depending on the
impact of ischemia (duration of reduced blood flow and infarct
location), this disease can cause various clinical manifestations.
Common afflictions are Paralysis or Hemiplegia, Aphasia,
problems associated with processes of memory and learning
and similar other effects (Kemp and McKernan, 2002). Stroke
is responsible for more than five million deaths each year
worldwide, making it the second highest leading cause of death
and a major cause of permanent mental and physical disability
(Wen et al., 2004; Zheng et al., 2010). Accordingly to the
World Health Organization (WHO) Argentina, Chile, Brazil and
Uruguay present 6–11 per 1000 affected persons in comparison
with 5–6 per 1000 habitants in South-America; being higher in
Brazil (11 per 1000) and lower in rural Bolivia (1 per 1000;
Lavados et al., 2007). Cerebrovascular accident is the second
cause of death in people over 45 years of age in Colombia
(Ministry of health and social protection, Colombia 2015). It is
estimated that one in six people may suffer at least one episode
of cerebral ischemia in life and only one in three survive as
patients that too in a state of physical dependence, such cases
could also develop dementia (Durukan and Tatlisumak, 2007).
Stroke remains one of the cause of high social and individual
cost of employee disability, leading to high spending on health
and generating a negative impact on the economy of the region
itself, therefore cerebral ischemia is a priority within the current
scientific research.
Several studies have demonstrated presence of senile plaques
(βA) and amyloid precursor protein (APP) in close proximity to
the ischemic focus (Ikeda et al., 2000; Shi et al., 2006), suggesting
a degree of convergence in the neuropathogenesis of cerebral
ischemia and AD (Zekry et al., 2003; Snyder et al., 2015; Kalaria
et al., 2016; Nelson et al., 2016). In stroke pathophysiology,
changes in the phosphorylation pattern of the Tau protein
during and after the ischemic event are observed (Wen et al.,
2004; Gutiérrez-Vargas et al., 2016). After infarction, the rapid
dephosphorylation of Tau occurs, and after blood reperfusion,
there is evidence of slow but steady hyperphosphorylation,
which causes an accumulation of the tau protein, resulting
in long-term brain damage (Wen et al., 2004). Additionally,
cerebral ischemia contributes to the development of cognitive
decline and dementia, which is induced by a sedentary lifestyle,
unhealthy eating habits, diabetes and other metabolic diseases
(Vijayan and Reddy, 2016). Epidemiological studies have also
shown that the prevalence of cognitive impairment in ischemic
stroke patients is nine-fold higher and controls at 3 months
and 4–12 times higher and controls 4 years after stroke, as
a result three out of four patients are probable to develop
dementia (Wen et al., 2004), predominantly AD-type (Pluta,
2004).
However, with respect to the cognitive impairment definition,
it is necessary to clarify that it is a clinical sign related
to cerebrovascular disease, but it has not been precisely
quantified as a vascular cognitive impairment (VCI) incidence
(Chui, 2005). Hence a vascular cognitive disorder spectrum
exists between VCI to VaD (Román et al., 2004). In general,
VaD is considered a deficit of new learning and memory
issues more than the pattern of motor slowing and executive
deficit. Some researchers suggest separated definitions, but
epidemiological studies suggest a continuum of AD’s disease and
vascular brain disease. Also, microvascular disease is correlated
with the advanced age, but not completely correlated with
cognitive impairment (Selnes and Vinters, 2006). Therefore,
a better understanding between vascular disease to cognitive
decline and dementia risk is necessary. Maybe an early
treatment of vascular affection may reduce the probability to
develop dementia (Stephan et al., 2009). Also, it is necessary
to unify some criteria for defining differential treatments,
depending upon the ethiopathogenesis of VCI, because most
of the risk factors are common to AD (Venkat et al.,
2015).
Recent scientific advances support that vascular risk factors
linked to cerebrovascular disease and stroke in the elderly,
significantly increase the risk of developing AD. These
include atherosclerosis, atrial fibrillation, coronary artery disease,
hypertension and diabetes mellitus. Moreover, review of various
autopsy series shows that 60%–90% of AD cases exhibit variable
cerebrovascular pathology. Although some vascular lesions
such as cerebral amyloid angiopathy, endothelial degeneration,
and periventricular white matter lesions are evident in most
cases of AD and a third would exhibit cerebral infarction
(Kalaria, 2000; Snyder et al., 2015; Kalaria et al., 2016). The
development and progression of both AD neuropathology
and cerebrovascular lesions in the central nervous system
are characterized by excitotoxicity. Activation of glial cells
and upregulation of inflammatory mediators (Sandu et al.,
2015), in a particular temporal, causes the disease progression
converging in neurovascular affection, loss of connectivity and
dementia. Indeed, maybe an anti-spreading of excitotoxicity and
anti-inflammatory approaches have proven to be beneficial in
the prevention and treatment of a wider spectrum of vascular
cognitive impairment and dementia (VCID).
CURRENT THERAPEUTICAL APPROACH:
AN INVITATION TO CHANGE THE
LIFESTYLE
Currently, exist several animal models that partially solve
the understanding of the neurodegenerative etiopathogenesis
and its treatment. However, when the potential therapies are
translated to humans it did not work or presented only a
limited action. Main difficulties are the diverse comorbility
associated to the cause and/or multiple affected brain regions.
This reduces the efficacy of some therapies that are limited to
a tissue-specific action or neurotransmission modulating types.
Global investigation suggests that a general prevention could
be achieved with the improvement in the quality of lifestyle,
including healthy diet, physical and mental activity, and avoiding
mechanical or chemical pro-inflammatory events in an early
stage of the most of non-communicable diseases (NIH, 2016;
WHO, 2016). Sedentary lifestyle, high calories ingest, little or
nil physical and mental activity, lead to metabolic disorders
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such as, hyperglycemia, dyslipidemia, hyperthension, diabetes,
tissue pro-immflamatory environment. These unhealthy
circumstances are a common cause of neurodegeneration due
to loss of kinases/phosphatases balance and reduces brain
plasticity, independently of the etiopathogenesis, which leads
to Sickness, Aging and high probability to develop VCID
(Figure 1A). Therefore, the best prevention of brain diseases
is to promote a healthy lifestyle, including balanced nutrition,
exercise, mental activity and social relationships apart from
providing motivation and integrated health to the people
(Figure 1B).
However, once it has started the disease must be defined
how and when to treat, which continues to being a big
challenge. Important progress has been made in understanding
the neurodegeneration progress in AD and its treatment, for
example; some medications have been approved by the FDA.
But therapeutical approaches provide only a modest relief of
cognitive symptoms, including disturbances in memory and
perception (Bassil and Grossberg, 2009; Neugroschl and Sano,
2009); ameliorating symptoms but do not alter the course of
disease progression and have even shown some undesired side
effects (Soreq and Seidman, 2001; Bassil and Grossberg, 2009;
Mimica and Presecki, 2009). Currently, available drugs for AD’s
treatment are glutamate modulators and acetyl-cholinesterase
(AChE) inhibitors with just palliative outreach. Glutamate
modulators continue being studied for improving its action
(Danysz and Parsons, 2012), because they have poor effect in
severe AD patients and carry several side effects. AChE has been
detected in senile plaques (Gomez-Ramos et al., 1992), and its
inhibition reduces the metabolic degradation of ACh slowing
the progression of cognitive dysfunction. In consequence, AChE
inhibitors are indicated in the early stage of the disease, delaying
the memory and attention deterioration. This treatment is
combined with other drugs for associated AD symptons, such as
depression, agitation, sleep disturbances, or later complications
like sphincter incontinence, urinary infections, ulcers and
thrombophlebitis caused by immobility. However, many of these
drugs have several side effects, such as diarrhea, dizziness,
loss of appetite, muscle cramps, nausea, fatigue, insomnia,
vomit, weight loss and hepatotoxicity, reducing the use of those
medicaments.
Other research have applied immunotherapy for AD
treatment, for example it has been developed that the AN-1792
vaccine (Tabira et al., 2011), which is a synthetic form of βA
protein, that could stimulate the immune system by eliminating
βA plaques and preventing emergence of new ones. But
adverse effects like development of meningoencephalitis
have been identified, resulting in non-approval of the
treatment (Delrieu et al., 2012). Currently, there are several
immunotherapy clinical trials in phase II and III, which
evaluate new strategies for blocking βA, or at least for
slowing the disease progression (Mangialasche et al., 2010).
For example, the placebo-controlled first prevention trial
of crenezumab immunotherapy developed by Genentech,
Banner and our research group ‘‘GNle of A’’, is being
evaluated with high risk members from families carrying
the E280A-PS1 AD mutation, before onset of mild cognitive
impairment (MCI) stage (Neurology, 2012). However, new
therapeutical agents capable of blocking cognitive impairment
progress in AD must be identified. At the same time it
is necessary to determine the critical event that triggers
the disease’s development, and for trying to offer not
only a slower or a palliative approach, but ideally to offer
a preventive or curative treatment without side effects
on the patient’s health. Currently these are not available
on the market.
On the other hand, today, according to the National Institute
of Infarction in USA, the only therapy approved by the FDA for
using in the first 4.5 h post-ischemic stroke is the thrombolytic
therapy with recombinant tissue plasmilógeno (tPA; Hanger
et al., 2007). This fibrinolytic process is a cost-effective treatment:
which does not increase process costs and is efficient because
it reduces post-infarction failure, resulting in a better quality
of life for patients and reduced health costs on the long
term (Rajan et al., 2015). However, the main limitation of
this treatment is the availability of short therapeutic window
between 3 h and 4.5 h post-stroke, also due to the stringent
inclusion and exclusion criteria very few patients have benefited.
Only between 20% and 25% of patients arrive on time to a
hospital, and between 3% and 5% of them are candidates for
thrombolysis, out of which approximately 50% are reperfused
(Auriel and Bornstein, 2010). Due to the complexity
of cerebrovascular disease, no effective therapies for
neuroprotection after acute window are available, that could
prevent or block or to reverse the progressive degeneration on
long term, as cognitive impairment and dementia. Therefore,
new therapeutical approaches are necessaries to find effective
and safety neuroprotective agents. In this review article,
we highlight gene therapy for a specific gene intervention,
and natural products and their derivatives as promising
candidates.
PRECLINICAL STUDIES AND MOLECULAR
TARGETS
For the last two decades, neuroprotective agents designed to
block death cascade have been investigated in animal models.
Numerous agents have been proposed to neurodegeneration in
rodent, rabbit and primate models (Yuede et al., 2007; Van
Dam and De Deyn, 2011). However, trying to solve difficulties
from different kind of risk factors in VCID, as age, diabetes,
hypertension, metabolic syndrome and some specific models
for VCID has been proposed (Helman and Murphy, 2016;
Madigan et al., 2016). Although there exist a big variability
between them (Venkat et al., 2015), and the most common
affection is the cognitive impairment. Therefore, an ‘‘ideal VCID
animal model’’ is not possible, because of the existence of a
wide spectrum in the definition and variation in animal models
of VCID. But each preclinical animal model under controlled
variable based in specific human VCI pathogenesis could give
light for intervention (Jiwa et al., 2010; Helman and Murphy,
2016). Also, considering that there exist a primary or secondary
convergence in the hippocampus alteration, the question could
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FIGURE 1 | Unhealthy lifestyle vs. dementia and therapeutical approach. (A) Hypothetical scheme representing how an unhealthy lifestyle could change the
cell environment, triggering imbalanced cell signaling and lossing intrinsic regulation (altered saturated/unsaturated phospholipid composition, spreading of
excitotoxicity, kinases/phosphates disbalance, pro-inflammatory response). Which could generate progressive affection of systemic functions (v.gr. metabolic
disorders, diabetes, hypertension, atherosclerosis), in general; and cerebral dysfunction in particular, inducing loss of connectivity, vascular cogntivie impairment and
dementia. (B) Convergent disbalance events in the brain after acute or chronic injury, which could be blocked by change of habits, or pharmacological and gene
therapies in pivotal events (blue bars). (C) Being the main difficulty to define the inclusion criteria and the intervention time for translational approach, but highlighting
the diverse therapeutical windows opportunities and phases of prevention of brain impairment.
be focused in to analyze the in vitro and in vivo vascular
implications.
On the other side, diverse kind of targets could be good
options for blocking the progression of brain impairment and
dementia (Anand et al., 2012), but this raises difficult questions
like; How to define the stem event, Temporal sequence of the
neurodegenerative processes, Sex and age dependent effects,
when and how to carry out the intervention as well as the
best analog situation in humans for a better safety and efficacy
properties?
Several research groups in SouthAmerica are working in
order to answer some of these questions, for example in
Brazil and Argentina. Further Chile is working on methods to
better understanding of neurodegeneration and looking for new
treatment strategies and biomarkers for early detection of AD
(Rojo et al., 2010; Beauquis et al., 2014; Vargas et al., 2014;
Martino Adami et al., 2015; Nunes et al., 2015) and VaD (Valério
Romanini et al., 2013; Schiavon et al., 2014; Silva et al., 2015;
Primo et al., 2016). In Colombia, some experimental designs
have been developed on ischemic stroke and Alzheimer’s animal
models trying to propose therapeutical approach that would
be versatile in the time (prevention, blocking progress and
reversion) as mentioned later.
For AD studies, triple-transgenic AD mice model
(3 × Tg-AD) is being used. The 3 × Tg-AD model harbors
the PS1 (M146V), APP (Swe), and tau (P301L) transgenes
(Oddo et al., 2003). The 3 × Tg-AD mice progressively develops
Aβ plaques (3–6 months) and NFTs (12 months). In addition,
3× Tg-AD exhibits synaptic dysfunction, including LTP deficits,
like those present in an age-related manner. These deficits in
long-term synaptic plasticity correlate with the accumulation of
intraneuronal βA and NTFs formation. Interestingly, silenced
BACE1 (main enzyme involved in the production of βA), in
the hippocampus using adenoassociated viral vectors reduces
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the hyperphosphorilation of tau (Piedrahita et al., 2016) and
improve cognitive function at 6 months and 12 months post-
treatment, presenting a balanced phospholipid composition,
by the reduction of saturated fatty acid (stearic acid (18:0),
palmitic acid (16:0)) and increase of poli-unsaturated fatty
acid (docosahexaenoic acid, DHA (22:6)), which prevented the
activation of pro-inflammatory signaling cPLA2/AA/COX2 in
old AD mice to long-term post-therapy (Villamil-Ortiz et al.,
2016). Also, the silencing of CDK5 in the CA1 hippocampal
area prevents the spreading of excitoxicity to other areas of
the neuronal circuit (Piedrahita et al., 2010; Castro-Alvarez
et al., 2014, 2015; Posada-Duque et al., 2015a) also reversing
(Piedrahita et al., 2010) or preventing neurodegeneration by
reduction of paired helicoidal formations (Castro-Alvarez
et al., 2014) and further, decreases the β amyloidosis
production (Castro-Alvarez et al., 2015). The result could
be assumed as it involves the prevention of Calpain activation
by reduction of the active p25/CDK5 complex formation
(Posada-Duque et al., 2015a) with a clear impact on the
down-regulation of phosphorilation rate of tau (Castro-
Alvarez et al., 2015), as well as regulation of phosphatases
and GSK3β activity (Castro-Alvarez et al., 2015). All of this,
would lead to the control of both histopathological hallmarks,
improving the neurotransmission and synaptic remodeling
(Posada-Duque et al., 2016); at the same time recovering
the complex synaptic molecular adhesion (p120 ctn/PSD95),
which has a consequential long-term effect (12 months) in
protection and improvement of cognitive function (Castro-
Alvarez et al., 2015; Uribe-Arias et al., 2016). Therefore,
safe and effective studies suggest that the BACE1 and
CDK5 RNAi-based therapy would be ready for a potential
translational trial in a patient with advanced or mild stage of
Alzheimer disease, without additional option for a curative
treatment.
On the other side, we take global and focal models of cerebral
ischemia. In the global model occlusion of two vessels analog
to a cardiac arrest is used, which develops hyperphosphorilated
tau and cognitive impairment (Gutiérrez-Vargas et al., 2010;
Castro-Alvarez et al., 2011). In the case of focal ischemia, the
occlusion of the middle cerebral artery (t-MCAO), is useful for
determining the infarct volume and the ischemic/reperfusion
stroke analog to human ischemic event. There is prevelance of
neurodegenerative hallmarks such as hyperphosphorilated tau,
microgliosis and cognitive impairment (Gutiérrez-Vargas et al.,
2015b, 2016).
Other previous research has been focused on the proposal
of therapeutical alternatives with atorvastatin after the first 6 h
(Céspedes-Rubio et al., 2010) and to long term post-cerebral
infarction (1 month; Gutiérrez-Vargas et al., 2014), this
remains valid and is potentially transferable to humans
without hemorrhagic risk. As an alternative to reduceing
neurological sequelae to a short and long term post-ischemia
(Gutiérrez-Vargas et al., 2015a). However, CDK5 silencing in
the hippocampus of ischemic rats has very impacting benefits,
because it reverses learning and relearning impairment caused
by cerebral ischemia, correlated with the prevention of neuronal
loss, decreased hyperphosphorylated tau, reactive astroglia
and microglia, within a month of post-ischemia/reperfusion
(Gutiérrez-Vargas et al., 2015b). CDK5 silencing effects remain
at 4 months post-ischemic, avoiding cognitive disturbance and
reversing neuropathological markers, showing a potentially
versatile use out of the current approved therapeutical
window or in any advance stage of the VCI post-ischemic
stroke. CDK5 RNAi-induced neurotransmission was a BDNF
(brain derivate neutrophic factor) dependent (Gutiérrez-
Vargas et al., 2016). Additional advantage shows that the
targeting of CDK5 in astrocytes has protective benefits,
because CDK5 RNAi induced a morphological-functional that
changes in the branching and BDNF release from astrocytes
protecting co-cultured neurons (Posada-Duque et al., 2015b)
and increases the endotelial adhesion in ischemic brain of
rats (Becerra-Calixto and Cardona-Gómez, 2016). In general,
these findings suggesting that CDK5 based therapy recover
the neurovascular unit integrity post-stroke (Posada-Duque
et al., 2014) and also, those findings support the potential
in translational studies in demented post-ischemic patients
as well.
Nevertheless, looking for other translational alternatives,
pharmacological therapy using natural products has a big
potential. Natural products have beenwidely used as antioxidants
or antiradicals agents, so that there are reports of inverse
relationship between a diet with foods rich in antioxidants
and the incidence of diseases (Sies, 1993). However, synthetic
antioxidants in the food industry have proven to be responsible
for liver damage and carcinogenesis and are less effective.
For this reason, the use of natural antioxidants investigation
has increased recently (Krishnaiah et al., 2010; Mecocci
and Polidori, 2012). Natural products have a wide variety
of biological effects: anti-inflammatory, anticancer, antiviral,
anti-thrombotic and among others (Lee et al., 2011; Yang et al.,
2014). In CNS diseases natural products have anti-convulsant
antioxidant, analgesic, anxiolytic, anti-depressant, being effective
in various pathologies. In addition, natural products are
considered as a source of potential molecules in the field
of neuroprotection (Lara-Guzman et al., 2012; Ho et al.,
2013; Sumi et al., 2013; Dong et al., 2014). Therefore,
in order to find pharmacological alternatives for a more
agile translation to humans, a systemic administration during
3 months in a late stage of the AD mice model has
been evaluated, using various natural products as flavonoids
by intraperitoneal administration and monoterpenes by oral
administration, which surpresively reduced the β-amyloidosis,
tauopathy, cognitive disorder and anxiety present in old
triple transgenic mice model of AD (Sabogal-Guáqueta et al.,
2015, 2016), which could be useful in different kind of
neurodegenerative environment and different advanced stages
with proinflammatory markers and synaptic deterioration as
VCID. Bioavailability analysis and scaling the production
will increase the possibility to develop a clinical trial from
South America. In summary, those experimental evidences
using gene and pharmacological therapies have suggested
that the neuroprotective capacity of different therapeutical
strategies, convergent in blocking the change of the membrane
phospholipid composition avoids the spreading of excitatory
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wave phenomenon and/or stopps the pro-inflammatory response
in the time (Figure 1B).
SENSOR OF NEURODEGENERATION: A
CONVERGENT CELL PHENOMENA IN
COGNITIVE IMPAIRMENT AND DEMENTIA
Many targets are viable as strategy for preventing
neurodegeneration, however based upon several evidences; the
hyperphosphorilation of tau is a key phenomena that reflect cell
imbalance associated to progressive brain impairment. Especially
in cognitive disorder and dementia by diferent ethiologies.
Tauopathy is a sensor of excitotoxicity, loss of homoeostasis,
metabolic disbalance, loss of kinases/phosphateses regulation,
consequences of pro-inflammatory environment, inductor of
plasticity and synaptic remodeling failure are the main hallmarks
of cognitive impairment and dementia (Figure 1).
AD and other tauopathies are progressive supranuclear palsy
(PSP), linked to chromosome 17 Parkinson, frontotemporal
dementia and cerebral ischemia, are characterized by a
phenomenon of hyperphosphorylation of tau protein, causing
changes in the microtubule (MT) assemblying-disassemblying
dynamics (Avila et al., 2004). Tau is dissociated from
MTs under the abnormal action of kinases and cytosolic
accumulated as paired helical filaments (PHFs) can be bound
forming NTFs (Grundke-Iqbal et al., 1986); However the
condition that facilitate aggregation and formation of those
structures are still unknown, stressing the importance for
deeper understanding of the cellular contexts involved in such
phenomenon.
Currently, 45 phosphorylation sites of tau in the brain of AD
have been identified along with its 441 amino acids—that are
involved in the formation of PHFs (Augustinack et al., 2002;
Hanger et al., 2009). In vitro experiments have shown that tau
is a substrate for multiple kinases including PKA, CaMKII,
PKC, MAPK, MARK, CDK5 and GSK3. Among these kinases,
CDK5 and GSK3 (along with their activators p35, p39, p25 and
p29), has been shown to phosphorylate tau in AD related epitopes
(Kobayashi et al., 1993; Paudel et al., 1993; Patrick et al., 1999).
Also, the hyperphosphorilation of tau is increased by transient
focal cerebral ischemia (Céspedes et al., 2013) and overall,
causes impaired spatial memory (Castro-Alvarez et al., 2011),
triggering in this process alteration of proteins that regulate
MT assemblying. Such as CDK5, GSK3 and actin cytoskeleton,
as RhoA (Céspedes-Rubio et al., 2010) and Rac (Gutiérrez-
Vargas et al., 2010), small GTPases proteins and phosphatases
as well. Damage of the neuronal cytoskeleton can be considered
as the main cause of the loss of protein transport and neuronal
instability in cerebral ischemia. MT disassemblying occurs after
ischemia and plays an important role in the pathophysiology of
this neurovascular disease (Pettigrew et al., 1996). Alterations
in the cytoskeleton partly reflect degradation and protein
aggregation after ischemia (Kühn et al., 2005). Degradation
and aggregation of MAP2 and Tau hyperphosphorylation are
biomarkers for the progression of ischemic damage (Pettigrew
et al., 1996), and are supported by some studies showing
immunoreactivity of tau in neurons and glia from thalamus,
hippocampus and cerebral cortex in brain slices from people who
suffered an ischemic event (Uchihara et al., 1995, 2000; Irving
et al., 1996) and also in experimental cerebral ischemia models
(Geddes et al., 1994; Dewar and Dawson, 1995; Irving et al.,
1996).
In general, recent studies suggest that the brain
pathophysiology of different kinds of VCID has a common
commitment of the kinases/phosphatases balance and
neurovascular integrity (Posada-Duque et al., 2014). And as
a potential marker of the tissue disequilibrium progression and
as a consequence of the chronic membrane composition and
cell signaling alteration, inducing cognitive impairment (Llorens
et al., 2016; Viswanathan et al., 2016), could be the taupathy
(Figure 1).
HUMAN PRECLINICAL STUDIES
Other strategic approach could be based in the casuistic of
pure dementias in the Latin-American region, which give an
exceptional opportunity to understand the pathogenesis in these
human populations with genetic risk, and go in favor of the basic
and clinical researchers interaction for a better understanding
and medical care of mix dementias, which have more complex
factors than pure ones.
The pure dementias are very rare. Most patients with
dementia have mixed factors leading to dementia. Therefore, It
is very common to notice AD patients with brain atrophy having
vascular changes characterized by cortical infarcts, subcortical or
cortico-suborticales and lecucoencefalopatía or signs of vascular
suffering of the white substance which correlates with mixed
dementias. Similarly, patients with VaD, also present atrophy and
neurodegenerative changes that are also difficult to identify as
pure case of dementia. Alzheimer’s disease and a pure case of
vascular dementia.
Therefore, it is important to note that autosomal dominant
AD is a pure Mendelian, neurodegenerative dementia and the
autosomal dominant VaD by CADASIL is a pure VaD, the rest
are vascular changes. The Mendelian autosomal dominant forms
of AD and CADASIL model are two ends of a single chain. One
is a model of neurodegeneration, while the other is a model
of vascular disease. The comparison between these two types
of dementias in clinical, neuro and pathophysiological levels
will allow us to differentiate a vascular vs. a neurodegenerative
dementia. But most importantly, these two models of dementia
allows genetic preclinical studies providing the possibility to
identify the healthy relatives carrying out the mutation in
presenilin or NOTCH3 respectively and is also ideal for
evaluating preventive therapies. But the more exceptional point
is that these affected populations with genetic AD and CADASIL
in Latin America come from large families with high average
number of children per family, allowing prevention studies in
population with those genetic risks.
On the other side, the search of AD treatments have evolved
in the recent years. Therapeutical strategies have changed
from palliative and symptomatic approach toward preventive
therapies, which are considered of three types: (a) tertiary
prevention therapies, consisting of treating affected population
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with MCI for preventing its conversion to dementia. Therefore,
tertiary prevention is not properly a preclinical therapy, but
it is an early intervention of the clinical phase of the disease.
(b) Secondary prevention studies are aimed to prevent the onset
of symptoms of AD in people who already have the disease’s
neuropathological changes. Currently, few studies of secondary
prevention therapies are being conducted, such as: Dominantly
Inherited Alzheimer’s Network Trials Unit (DIAN-TU), testing
Gantenerumab, an aggregated anti-βA antibody, and A4 (Anti-
Amyloid treatment in Asymptomatic Alzheimer’s) trial, using
Solanezumab (a soluble anti-βA antibody); which invite to
clinically normal individuals of 65–85 years old with elevated
fibrillar amyloid in brain detected by PET Amyloid to be
treated (Doody et al., 2014), each drug compared to the pooled
placebo. API COLOMBIA, Alzheimer’s Prevention Initiative
(API-Colombia) in Latin America, which is evaluating the
passive β-amyloid (βA) immunization therapy Crenezumab in
cognitively unaffected persons 30–60 years old from the world’s
largest known ADAD kindred in Antioquia, Colombia (Reiman
et al., 2011); and API APOE4 Trial in USA will evaluate an
immunization therapy in 60–75 year-old cognitively unimpaired
APOE4 homozygotes. And finally, in studies of primary
prevention (c), the aim is to prevent the onset of
neuropathological changes of the people with high risk.
However, nobody is conducting studies of primary prevention
for AD or other kind of dementia. Therefore, the challenge for
future is to design and to develop primary prevention studies
in people with high risk for developing the disease, without
symptoms or neuropathological changes. Here exist a big
opportunity for developing this kind of studies, because it has
been identified that there are more than 400 young carriers in
the E280A FAD population.
TRANSLATIONAL PERSPECTIVE IN
SOUTH AMERICA: CHALLENGES AND
PITFALLS
Despite having identified potential molecular targets, there are
considerable limitations inherent to the nervous system, such as
crossing the blood-brain barrier and the difficulty for targeting
specific neuronal populations. The presence of these obstacles
has prompted the search for new strategies for the treatment
of neurodegenerative diseases, using viral vectors, design of
nanoparticle for improving delivery, and future approaches by
systemic administration vectors or functionalized nutrition, but
including safety and efficacy of the treatment remains a major
challenge.
In addition to those inherent difficulties of the central
nervous system, general translation of drug discovery to clinical
usefulness needs to overcome several limitations, such as
sensibility, specificity, well stratified patients, correct analytical
approaches and differentiation from others (Drucker and
Krapfenbauer, 2013). However, to promove the translation of
therapeutical alternatives impacting morbility and mortality is
an urgent necessity around the world and mainly in South
American countries. More specifically in Colombia, there is a
need to formulate policies and procedures on the subject in
addition to developing a quality emergency for medical care
for acute injuries (Razzak and Kellermann, 2002). Also, we
need to catch up in normatives and protocols for developing
clinical trials with original candidates or strategies proposed
from our South American countries; and a concerted effort
from scientists, medical specialists, pharmaceutical industry
and government, accompanied by economical and social
support. We should be able to offer experimental treatments,
without false expectations to the patient/family, based in
the rigorousness of the scientific preclinical evidences, a
close and direct dialog with the medical team, peer-review
vigilance of the I, II and III phases, and strict long-term
monitoring of the potential unwanted side-effects (Main et al.,
2014), are also essential. This would progressively strengthen
the contribution for solving the increased mental health
problems.
Now, focused in the pathogenesis, one of the most difficult
aspect for developing a new strategy to block or to prevent
neurodegeneration is to define a therapeutical window and its
versatility to similar disorders such as VCID. For example, AD is
a progressive disorder apparently preceded by a dormant period
of several years, sometimes even decades before cognitive decline
is evident. This normally makes it difficult to establish a suitable
time window for initiating treatment. But after ischemic stroke
there exist a high probability to develop cognitive impairment
within weeks or months (Snyder et al., 2015; Kalaria et al., 2016),
but there are no available preventive therapy. Interestingly,
both neurological disorders present common phenomena like
cognitive impairment and dementia that could be blocked using
similar strategies. The challenge is when to intervent in each type
of neurodegenerative process? (Figure 1C). Some experimental
studies comparing tauopathy in Alzheimer’s animal model
and ischemic stroke in rats, show that in both models exist
an intrinsic homeostasis in an early period itself. But, due
to loss of time this intrinsic balance is lost (Villamil-Ortiz
and Cardona-Gómez, 2015; Madigan et al., 2016), generating
intermediate and late period of degenerative progress that
reflect in hyperphosphorylation of tau leading to loss of
connectivity, therefore, this could be the common phenomenon
to attack in any potential moment of the triggered cascade
(Figure 1C).
In Colombia, the development of clinical trials with
our own discovered therapeutical candidates have not been
developed yet. A primary prevention therapy would impact
the affected population and would be a boost for solving
related diseases, for example like in young carriers of AD
or CADASIL mutation. However, trying to put together the
different and existing barriers, these are necessary: (a) discuss
the inclusion and exclusion criteria of the translational medicine
by interdisciplinary team of a project or institution; (b) it is
necessary to prepare and to present a clinical trial protocol to
a national regulatory entity, for its approval, seeking particular
adjustment in each Latin American country; (c) to convince
an investment agency of the need to support a clinical trial
with support from original proposal from developing countries;
(d) proceed step by step in the advancement of the clinical phase
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to the benefit as many people as possible. Finally, if this could be
achieved, then it would result in providing a boost to the scientific
and biotechnology development of the region.
CONCLUSION
Society is being more exposed to dangerous environment
and habits that induces chronic diseases, physical and mental
disabilities. A Stronger Public Health normatives and social
programs for prevention of unhealthy lifestyle must be
developed. Non transmisible disorder triggering cognitive
impairment and dementia and existing rigorous preclinical
evidences that block or reverse the brain pathology disorders
as presented above either by using silencing gene therapy
or by systemic treatments with natural products should be
further studied and researched. Colombia and South American
countries should invest and support clinical trials with the
understanding of the casuistic of pure dementias in patients
for developing primary prevention methods. But at the
same time should moderate it by normative and adequate
vigilance from peer-reviewers for long-term monitoring of
the potential unwanted side-effects. This action would be a
great strategy for the scientific and biotechnology development
of the region, and a worthy contribution to solve a major
health problem.
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